Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis.

Fardin NabizadehMobin MohamadiShayan RahmaniRayan RajabiFatemeh AfrashtehSoroush NajdaghiOmid Mirmosayyeb

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2023)

Our results showed acceptable safety and efficacy for cladribine for the treatment of MS except in terms of reducing EDSS. Combination of our findings with the results of previous studies which compared cladribine to other disease-modifying therapies (DMTs), cladribine seems to be a safe and effective drug in achieving better treatment for relapsing-remitting MS (RRMS) patients.

Keyphrases

multiple sclerosis
end stage renal disease
mass spectrometry
ms ms
chronic kidney disease
prognostic factors
rheumatoid arthritis
combination therapy
systemic lupus erythematosus
patient reported outcomes
drug induced
disease activity